COVID-19

December 14, 2020

Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK | FDA issues Emergency Use Authorization for first COVID-19 vaccine

December 7, 2020

Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19 | The Advisory Committee on Immunization Practices’ Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine — United States, 2020 | Updated CDC guidance on when to quarantine

November 30, 2020

AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19 | Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results | Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19 | A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

November 23, 2020

Immunological memory to SARS-CoV-2 assessed for greater than six months after infection | Sixty-Day Outcomes Among Patients Hospitalized With COVID-19 | Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany | FDA Authorizes First COVID-19 Test for Self-Testing at Home

November 16, 2020

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans | Pfizer and BioNTech announce vaccine candidate against COVID-19 achieved success in first interim analysis from phase 3 study | FDA Authorizes Monoclonal Antibody for Treatment of COVID-19

Physician taking masked patient's blood pressure

November 5, 2020

Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology | SARS-CoV-2 direct cardiac damage through spike-mediated cardiomyocyte 3 fusion | Prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised cancer patient.

October 26, 2020

An inflammatory cytokine signature predicts COVID-19 severity and survival | Moderna phase III clinical study protocol | Pfizer phase III clinical study protocol | Identifying Optimal COVID-19 Testing Strategies for Schools and Businesses: Balancing Testing Frequency, Individual Test Technology, and Cost

October 16, 2020

Smell and taste changes are early indicators of the COVID-19 pandemic and political decision effectiveness | Vascular Disease and Thrombosis in SARS-CoV-2- Infected Rhesus Macaques | COVID-19 and Excess All-Cause Mortality in the US and 18 Comparison Countries

October 8, 2020

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 | Rethinking Covid-19 Test Sensitivity — A Strategy for Containment | Adolescent with COVID-19 as the Source of an Outbreak at a 3-Week Family Gathering — Four States, June–July 2020 | Trends in COVID-19 Incidence After Implementation of Mitigation Measures — Arizona, January 22–August 7, 2020

September 29, 2020

Case-Control Study of Use of Personal Protective Measures and Risk for Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Thailand | Characteristics and Maternal and Birth Outcomes of Hospitalized Pregnant Women with Laboratory-Confirmed COVID-19 — COVID-NET, 13 States, March 1–August 22, 2020 | Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Parasites Without Borders

A comprehensive educational resource on all aspects of parasitic diseases and their impact on humanity around the globe.

Donate to Parasites Without Borders today!

Help bring the latest medical and basic biological information pertaining to diseases caused by eukaryotic parasites to every practicing physician and medical student within the United States. 

Scroll to Top